Press Releases

Huateng Pharma, a pioneering force in pharmaceutical innovation, is delighted to announce the launch of advanced anti-diabetes intermediates, including intermediates of Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide. These state-of-the-art compounds, detailed at [https://us.huatengsci.com/product/175.html], signify a significant leap forward in the fight against diabetes.

Huateng Pharma's Research and Development Director expressed the company's excitement about the potential impact of these intermediates on diabetes drug development, stating, "Our breakthrough anti-diabetes intermediates mark a new era in drug development. The high purity of Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide intermediates positions them as vital tools for creating more effective and targeted diabetes treatments."

These groundbreaking intermediates, meticulously developed by Huateng Pharma's dedicated team of researchers, promise to play a crucial role in advancing the field of diabetes therapeutics. Their high purity ensures the reliability and consistency necessary for the development of safe and effective medications.

In addition to unveiling these cutting-edge compounds, Huateng Pharma is proud to announce its readiness to offer Contract Development and Manufacturing Organization (CDMO) services. This strategic move aims to foster collaboration within the pharmaceutical industry and provide organizations with access to Huateng Pharma's expertise in anti-diabetes drug development.

"We recognize the importance of collaboration in advancing pharmaceutical solutions. By offering CDMO services, we aim to facilitate partnerships that drive innovation in diabetes drug development. Our high-purity intermediates serve as a foundation for reliable and consistent drug formulations," added the R&D Director.

For further information or collaboration inquiries, interested parties are encouraged to contact Huateng Pharma at sales@huatengusa.com or visit the official website at [https://us.huatengsci.com]. Huateng Pharma looks forward to forging impactful collaborations that contribute to the advancement of diabetes treatment.

About Huateng Pharma

Hunan Huateng Pharmaceutical Co., Ltd is a world-leading CDMO for intermediates from R&D lab supply to commercial production. For more information, please visit [https://us.huatengsci.com].